Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation
Standard
Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. / Widenmeyer, Melanie; Shebzukhov, Yuriy; Haen, Sebastian P; Schmidt, Diethard; Clasen, Stephan; Boss, Andreas; Kuprash, Dmitri V; Nedospasov, Sergei A; Stenzl, Arnulf; Aebert, Hermann; Wernet, Dorothee; Stevanović, Stefan; Pereira, Philippe L; Rammensee, Hans-Georg; Gouttefangeas, Cécile.
In: INT J CANCER, Vol. 128, No. 11, 01.06.2011, p. 2653-62.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation
AU - Widenmeyer, Melanie
AU - Shebzukhov, Yuriy
AU - Haen, Sebastian P
AU - Schmidt, Diethard
AU - Clasen, Stephan
AU - Boss, Andreas
AU - Kuprash, Dmitri V
AU - Nedospasov, Sergei A
AU - Stenzl, Arnulf
AU - Aebert, Hermann
AU - Wernet, Dorothee
AU - Stevanović, Stefan
AU - Pereira, Philippe L
AU - Rammensee, Hans-Georg
AU - Gouttefangeas, Cécile
N1 - Copyright © 2010 UICC.
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Radiofrequency (RF) ablation is a minimally invasive technique routinely applied for the treatment of primary and secondary liver tumors. It induces cell death by thermal coagulative necrosis of tumor tissues, whereas cellular metabolism can still take place in a transition zone surrounding the necrotic area. An increase in heat shock protein expression occurs shortly after treatment, suggesting that the induction of activating signals may stimulate the host immune system. In addition, various effects on immune effectors have also been observed, including stimulation of tumor-directed T lymphocytes. Here, we prospectively assessed the activation of tumor antigen-specific antibodies, as well as antigen-specific CD4(+) and CD8(+) T cells in patients suffering from primary or secondary malignancies and treated by RF ablation with or without concomitant chemotherapy. An increase of antibodies (in 4 patients of 49), CD4(+) T cells or CD8(+) T cells (in 2 patients of 49) could be detected several weeks to months following intervention. These findings suggest that in addition to the local control of tumor growth, RF ablation can provide the appropriate conditions for activating tumor-antigen specific immune responses.
AB - Radiofrequency (RF) ablation is a minimally invasive technique routinely applied for the treatment of primary and secondary liver tumors. It induces cell death by thermal coagulative necrosis of tumor tissues, whereas cellular metabolism can still take place in a transition zone surrounding the necrotic area. An increase in heat shock protein expression occurs shortly after treatment, suggesting that the induction of activating signals may stimulate the host immune system. In addition, various effects on immune effectors have also been observed, including stimulation of tumor-directed T lymphocytes. Here, we prospectively assessed the activation of tumor antigen-specific antibodies, as well as antigen-specific CD4(+) and CD8(+) T cells in patients suffering from primary or secondary malignancies and treated by RF ablation with or without concomitant chemotherapy. An increase of antibodies (in 4 patients of 49), CD4(+) T cells or CD8(+) T cells (in 2 patients of 49) could be detected several weeks to months following intervention. These findings suggest that in addition to the local control of tumor growth, RF ablation can provide the appropriate conditions for activating tumor-antigen specific immune responses.
KW - Aged
KW - Antibodies, Neoplasm/immunology
KW - Antigens, Neoplasm/immunology
KW - CD4-Positive T-Lymphocytes/immunology
KW - CD8-Positive T-Lymphocytes/immunology
KW - Catheter Ablation
KW - Female
KW - Humans
KW - Middle Aged
KW - Neoplasms/immunology
KW - Prognosis
KW - Prospective Studies
U2 - 10.1002/ijc.25601
DO - 10.1002/ijc.25601
M3 - SCORING: Journal article
C2 - 20715115
VL - 128
SP - 2653
EP - 2662
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 11
ER -